Tsuyoshi Hamada1, Li Liu2, Jonathan A Nowak3, Kosuke Mima4, Yin Cao5, Kimmie Ng4, Tyler S Twombly1, Mingyang Song6, Seungyoun Jung7, Ruoxu Dou4, Yohei Masugi1, Keisuke Kosumi1, Yan Shi8, Annacarolina da Silva1, Mancang Gu9, Wanwan Li1, NaNa Keum10, Kana Wu11, Katsuhiko Nosho12, Kentaro Inamura13, Jeffrey A Meyerhardt4, Daniel Nevo14, Molin Wang15, Marios Giannakis16, Andrew T Chan17, Edward L Giovannucci11, Charles S Fuchs18, Reiko Nishihara19, Xuehong Zhang20, Shuji Ogino21. 1. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 2. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology and Biostatistics, The Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Hubei, PR China. 3. Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 5. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. 6. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 7. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA. 8. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Chinese PLA General Hospital, Beijing, PR China. 9. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; College of Pharmacy, Zhejiang Chinese Medical University, Zhejiang, PR China. 10. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Food Science and Biotechnology, Dongguk University, Goyang, Republic of Korea. 11. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 12. Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan. 13. Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. 14. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 15. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 16. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 17. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 18. Yale Cancer Center, New Haven, CT, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA; Smilow Cancer Hospital, New Haven, CT, USA. 19. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 20. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: xuehong.zhang@channing.harvard.edu. 21. Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: shuji_ogino@dfci.harvard.edu.
Abstract
BACKGROUND: High-level plasma 25-hydroxyvitamin D [25(OH)D] has been associated with lower colorectal cancer incidence and mortality. Considering evidence indicating immunomodulatory effects of vitamin D, we hypothesised that survival benefits from high systemic vitamin D level might be stronger for colorectal carcinoma with lower immune response to tumour. METHODS: Using 869 colon and rectal cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study, we assessed the prognostic association of postdiagnosis 25(OH)D score [derived from diet and lifestyle variables to predict plasma 25(OH)D level] in strata of levels of histopathologic lymphocytic reaction. The Cox proportional hazards regression model was adjusted for potential confounders, including microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, PTGS2 (cyclooxygenase-2) expression and KRAS, BRAF and PIK3CA mutations. RESULTS: The association of postdiagnosis 25(OH)D score with colorectal cancer-specific mortality differed by levels of peritumoural lymphocytic reaction (pinteraction = 0.001). Multivariable-adjusted mortality hazard ratios for a quintile-unit increase of 25(OH)D score were 0.69 [95% confidence interval (CI), 0.54-0.89] in cases with negative/low peritumoural lymphocytic reaction, 1.08 (95% CI, 0.93-1.26) in cases with intermediate peritumoural reaction and 1.25 (95% CI, 0.75-2.09) in cases with high peritumoural reaction. The survival association of the 25(OH)D score did not significantly differ by Crohn's-like lymphoid reaction, intratumoural periglandular reaction or tumour-infiltrating lymphocytes. CONCLUSIONS: The association between the 25(OH)D score and colorectal cancer survival is stronger for carcinomas with lower peritumoural lymphocytic reaction. Our results suggesting interactive effects of vitamin D and immune response may contribute to personalised dietary and lifestyle intervention strategies.
BACKGROUND: High-level plasma 25-hydroxyvitamin D [25(OH)D] has been associated with lower colorectal cancer incidence and mortality. Considering evidence indicating immunomodulatory effects of vitamin D, we hypothesised that survival benefits from high systemic vitamin D level might be stronger for colorectal carcinoma with lower immune response to tumour. METHODS: Using 869 colon and rectal cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study, we assessed the prognostic association of postdiagnosis 25(OH)D score [derived from diet and lifestyle variables to predict plasma 25(OH)D level] in strata of levels of histopathologic lymphocytic reaction. The Cox proportional hazards regression model was adjusted for potential confounders, including microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, PTGS2 (cyclooxygenase-2) expression and KRAS, BRAF and PIK3CA mutations. RESULTS: The association of postdiagnosis 25(OH)D score with colorectal cancer-specific mortality differed by levels of peritumoural lymphocytic reaction (pinteraction = 0.001). Multivariable-adjusted mortality hazard ratios for a quintile-unit increase of 25(OH)D score were 0.69 [95% confidence interval (CI), 0.54-0.89] in cases with negative/low peritumoural lymphocytic reaction, 1.08 (95% CI, 0.93-1.26) in cases with intermediate peritumoural reaction and 1.25 (95% CI, 0.75-2.09) in cases with high peritumoural reaction. The survival association of the 25(OH)D score did not significantly differ by Crohn's-like lymphoid reaction, intratumoural periglandular reaction or tumour-infiltrating lymphocytes. CONCLUSIONS: The association between the 25(OH)D score and colorectal cancer survival is stronger for carcinomas with lower peritumoural lymphocytic reaction. Our results suggesting interactive effects of vitamin D and immune response may contribute to personalised dietary and lifestyle intervention strategies.
Authors: Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-03-17 Impact factor: 23.059
Authors: Surojit Sarkar; Martin Hewison; George P Studzinski; Yan Chun Li; Vandana Kalia Journal: Crit Rev Clin Lab Sci Date: 2015-10-19 Impact factor: 6.250
Authors: Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song Journal: Gut Date: 2018-02-06 Impact factor: 23.059
Authors: Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N Glickman; Cristina R Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L Giovannucci; Charles S Fuchs Journal: Clin Cancer Res Date: 2009-10-13 Impact factor: 12.531
Authors: Katsuhiko Nosho; Natsumi Irahara; Kaori Shima; Shoko Kure; Gregory J Kirkner; Eva S Schernhammer; Aditi Hazra; David J Hunter; John Quackenbush; Donna Spiegelman; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino Journal: PLoS One Date: 2008-11-12 Impact factor: 3.240
Authors: K Ng; B M Wolpin; J A Meyerhardt; K Wu; A T Chan; B W Hollis; E L Giovannucci; M J Stampfer; W C Willett; C S Fuchs Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Jonna Berntsson; Maria C Svensson; Karin Leandersson; Björn Nodin; Patrick Micke; Anna H Larsson; Jakob Eberhard; Karin Jirström Journal: Int J Cancer Date: 2017-07-20 Impact factor: 7.396
Authors: Elizabeth Loehrer; Rebecca A Betensky; Edward Giovannucci; Li Su; Andrea Shafer; Bruce W Hollis; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Keisuke Kosumi; Tsuyoshi Hamada; Sui Zhang; Li Liu; Annacarolina da Silva; Hideo Koh; Tyler S Twombly; Kosuke Mima; Teppei Morikawa; Mingyang Song; Jonathan A Nowak; Reiko Nishihara; Leonard B Saltz; Donna Niedzwiecki; Fang-Shu Ou; Tyler Zemla; Robert J Mayer; Hideo Baba; Kimmie Ng; Marios Giannakis; Xuehong Zhang; Kana Wu; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Jeffrey A Meyerhardt; Shuji Ogino Journal: Eur J Cancer Date: 2019-03-01 Impact factor: 9.162
Authors: Tomotaka Ugai; Koichiro Haruki; Juha P Väyrynen; Jennifer Borowsky; Kenji Fujiyoshi; Mai Chan Lau; Naohiko Akimoto; Rong Zhong; Junko Kishikawa; Kota Arima; Shan-Shan Shi; Melissa Zhao; Charles S Fuchs; Xuehong Zhang; Marios Giannakis; Mingyang Song; Hongmei Nan; Jeffrey A Meyerhardt; Molin Wang; Jonathan A Nowak; Shuji Ogino Journal: Mayo Clin Proc Date: 2022-01 Impact factor: 11.104
Authors: Said Izreig; Michael Hajek; Heather A Edwards; Saral Mehra; Clarence Sasaki; Benjamin L Judson; Rahmatullah W Rahmati Journal: Laryngoscope Investig Otolaryngol Date: 2020-11-03
Authors: Frank A Sinicrope; Qian Shi; Thomas C Smyrk; Richard M Goldberg; Steven J Cohen; Sharlene Gill; Morton S Kahlenberg; Suresh Nair; Anthony F Shield; Balkrishna N Jahagirdar; Sawyer B Jacobson; Nathan R Foster; Michael N Pollak; Steven R Alberts Journal: JNCI Cancer Spectr Date: 2021-07-23
Authors: Myong-Won Seo; Jong Kook Song; Hyun Chul Jung; Sung-Woo Kim; Jung-Hyun Kim; Jung-Min Lee Journal: Int J Environ Res Public Health Date: 2019-09-14 Impact factor: 3.390